Long-term Course and Cardiac Sympathetic Nerve Activity in Patients with Hypertrophic Cardiomyopathy

Overview

Journal Br Heart J

Specialty Cardiology & Vascular Diseases

Date 1992 Feb 1

PMID 1540436

Citations 9

Authors

M Shimizu

N Sugihara

Y Kita

K Shimizu

Y Horita

K Nakajima

J Taki

R Takeda

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the relation between regional myocardial sympathetic nerve activity and the electrocardiographic and cardiac functional changes in hypertrophic cardiomyopathy.

Design: A retrospective study to compare the findings of myocardial scintigraphy with iodine-123 metaiodobenzylguanidine (MIBG) and the serial electrocardiographic changes.

Setting: Myocardial scintigraphy was performed with iodine-123 MIBG and thallium-201 and single photon emission computed tomography (SPECT) in the division of nuclear medicine of Kanazawa University Hospital. Both SPECT studies were performed within a week.

Patients: 22 patients with hypertrophic cardiomyopathy classified according to their serial electrocardiographic changes--namely, 15 patients with an increase in or the appearance of a negative T wave (group A) and seven patients with a conduction disturbance or a decrease in or disappearance of the negative T wave (group B). The mean follow up period was 45 (range 12-143) months.

Results: Group B showed a high rate of decreased activity or defects in MIBG uptake compared with group A (p less than 0.005). The areas of decreased activity or defects corresponded with the hypertrophied portion of the left ventricular wall. Although the early myocardial uptake (MIBG: thallium ratio) was similar in both groups, the mean (SD) MIBG clearance rate was significantly higher (p less than 0.05) in group B (0.25 (0.17)) than in group A (0.10 (0.15)).

Conclusion: Abnormalities of regional myocardial sympathetic nerve activity may be important in patients with hypertrophic cardiomyopathy and suspected progression of myocardial damage.

Citing Articles

Cardiac I-IBG Imaging in Heart Failure.

Verschure D, Nakajima K, Verberne H Pharmaceuticals (Basel). 2022; 15(6).

PMID: 35745574 PMC: 9230638. DOI: 10.3390/ph15060656.

Cardiac sympathetic activity in hypertrophic cardiomyopathy and Tako-tsubo cardiomyopathy.

Verschure D, van Eck-Smit B, Somsen G, Verberne H Clin Transl Imaging. 2015; 3(5):379-385.

PMID: 26457274 PMC: 4592489. DOI: 10.1007/s40336-015-0133-z.

Differential Role of Leptin and Adiponectin in Cardiovascular System.

Ghantous C, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A Int J Endocrinol. 2015; 2015:534320.

PMID: 26064110 PMC: 4433709. DOI: 10.1155/2015/534320.

Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias.

Terai H, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Sakata K J Nucl Cardiol. 2003; 10(3):304-10.

PMID: 12794630 DOI: 10.1016/s1071-3581(03)00362-3.

MIBG imaging.

Patel A, Iskandrian A J Nucl Cardiol. 2002; 9(1):75-94.

PMID: 11845133 DOI: 10.1067/mnc.2002.121471.

References

James T, MARSHALL T . De subitaneis mortibus. XII. Asymmetrical hypertrophy of the heart. Circulation. 1975; 51(6):1149-66. DOI: 10.1161/01.cir.51.6.1149. View

Wieland D, Brown L, Rogers W, Worthington K, Wu J, Clinthorne N . Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981; 22(1):22-31. View

Horita Y, GENDA A, Shimizu M, Sugihara N, SUEMATSU T, Kita Y . Serial electrocardiographic and angiographic changes of patients with hypertrophic cardiomyopathy. Jpn Circ J. 1989; 53(11):1327-42. DOI: 10.1253/jcj.53.1327. View

Henderson E, Kahn J, Corbett J, Jansen D, Pippin J, Kulkarni P . Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988; 78(5 Pt 1):1192-9. DOI: 10.1161/01.cir.78.5.1192. View

Spirito P, Maron B, Bonow R, Epstein S . Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987; 60(1):123-9. DOI: 10.1016/0002-9149(87)90998-2. View

Nagata S, Park Y, Minamikawa T, Yutani C, Kamiya T, Nishimura T . Thallium perfusion and cardiac enzyme abnormalities in patients with familial hypertrophic cardiomyopathy. Am Heart J. 1985; 109(6):1317-22. DOI: 10.1016/0002-8703(85)90358-8. View

McKenna W, Borggrefe M, England D, Deanfield J, Oakley C, Goodwin J . The natural history of left ventricular hypertrophy in hypertrophic cardiomyopathy: an electrocardiographic study. Circulation. 1982; 66(6):1233-40. DOI: 10.1161/01.cir.66.6.1233. View

Fujiwara H, Onodera T, Tanaka M, Shirane H, Kato H, Yoshikawa J . Progression from hypertrophic obstructive cardiomyopathy to typical dilated cardiomyopathy-like features in the end stage. Jpn Circ J. 1984; 48(11):1210-4. DOI: 10.1253/jcj.48.1210. View

Thompson D, Naqvi N, Juul S, Swanton R, Coltart D, Jenkins B . Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J. 1980; 44(5):488-98. PMC: 482433. DOI: 10.1136/hrt.44.5.488. View

10.

PASTERNAC A, Noble J, Streulens Y, Elie R, Henschke C, Bourassa M . Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation. 1982; 65(4):778-89. DOI: 10.1161/01.cir.65.4.778. View

11.

Wieland D, Wu J, Brown L, Mangner T, Swanson D, BEIERWALTES W . Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980; 21(4):349-53. View

12.

Kline R, Swanson D, Wieland D, Thrall J, Gross M, Pitt B . Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981; 22(2):129-32. View

13.

Ten Cate F, Roelandt J . Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. Am Heart J. 1979; 97(6):762-5. DOI: 10.1016/0002-8703(79)90012-7. View

14.

Maron B, Epstein S, Roberts W . Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 1979; 43(6):1086-102. DOI: 10.1016/0002-9149(79)90139-5. View

15.

Sole M, Lo C, LAIRD C, SONNENBLICK E, Wurtman R . Norepinephrine turnover in the heart and spleen of the cardiomyopathic Syrian hamster. Circ Res. 1975; 37(6):855-62. DOI: 10.1161/01.res.37.6.855. View

16.

Tanigawa G, Jarcho J, Kass S, Solomon S, Vosberg H, Seidman J . A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell. 1990; 62(5):991-8. DOI: 10.1016/0092-8674(90)90273-h. View

17.

Weber K, Janicki J, Shroff S, Pick R, Chen R, BASHEY R . Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 1988; 62(4):757-65. DOI: 10.1161/01.res.62.4.757. View

18.

Yutani C, Imakita M, Ishibashi-Ueda H, Hatanaka K, Nagata S, Sakakibara H . Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy. Am Heart J. 1985; 109(3 Pt 1):545-53. DOI: 10.1016/0002-8703(85)90561-7. View

19.

OGara P, Bonow R, Maron B, Damske B, van Lingen A, Bacharach S . Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation. 1987; 76(6):1214-23. DOI: 10.1161/01.cir.76.6.1214. View

20.

Sisson J, Shapiro B, Meyers L, Mallette S, Mangner T, Wieland D . Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987; 28(10):1625-36. View